| 郑瑶瑶.扶正抗癌方联合奥希替尼治疗EGFR突变阳性晚期非小细胞肺癌的疗效及对胸腔积液MMP-9、PD-L1水平的影响[J].浙江中西医结合杂志,2026,36(3): |
| 扶正抗癌方联合奥希替尼治疗EGFR突变阳性晚期非小细胞肺癌的疗效及对胸腔积液MMP-9、PD-L1水平的影响 |
|
| 投稿时间：2025-03-17 修订日期：2025-05-13 |
| DOI： |
| 中文关键词: 非小细胞肺癌 奥希替尼 突变阳性 扶正抗癌方 肿瘤标志物 |
| 英文关键词:Non small cell lung cancer Osimertinib Mutation positive Fuzheng Kang"ai formula Tumor markers |
| 基金项目:嘉兴市科技计划项目,编号:2023AD31105 |
|
| 摘要点击次数: 59 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:探讨扶正抗癌方+奥希替尼对表皮生长因子受体(EGFR)突变阳性晚期非小细胞肺癌(NSCLC)治疗的效果,及对患者肿瘤标志物、不良反应等的影响。方法:选取在本院治疗的晚期EGFR突变阳性NSCLC患者102例,随机分为参照组、观察组。参照组采用奥希替尼治疗,观察组加用扶正抗癌方。比较两组总有效率、血管生成因子、肿瘤标志物、胸腔积液生化指标、生活质量及安全性分析。结果:观察组总有效率(56.86%)显著高于参照组(35.29%)(P<0.05),癌胚抗原(CEA)、程序性死亡受体配体-1(PD-L1)、糖类抗原125(CA125)、转化生长因子β1(TGF-β1)、基质金属蛋白酶(MMP-9)、血管内皮生长因子(VEGF)水平显著低于参照组(P<0.05)；观察组卡氏功能状态量表(KPS)评分显著高于参照组(P<0.05)；且两组血小板减少、胃肠道反应等发生率无显著性差异(P>0.05)。结论:晚期EGFR突变阳性NSCLC患者接受扶正抗癌方与奥希替尼联合方案干预,可有效杀伤肿瘤细胞,缓解疾病症状,有一定临床应用价值。 |
| 英文摘要: |
| Objective: To investigate the therapeutic effect of union of Fuzheng Kang"ai formula and osimertinib on advanced non-small cell lung cancer (NSCLC) with positive epidermal growth factor receptor (EGFR) mutation, and its impacts on tumor markers and untoward reactions. Methods: Totally 102 patients with advanced EGFR mutation positive NSCLC treated in our hospital were grouped into reference group and monitored group randomly. The reference group adopted osimertinib, while the monitored group additionally adopted Fuzheng Kang"ai formula. The total effective rate, angiogenic factors, tumor markers, biochemical indicators of pleural effusion, quality of life, and safety were compared. Results: The monitored group had a clearly higher total effective rate (56.86%) than reference group (35.29%) (P<0.05), and clearly lower carcinoembryonic antigen (CEA), programmed cell death ligand-1 (PD-L1), carbohydrate antigen 125 (CA125), transforming growth factor-β1 (TGF-β1), matrix metalloproteinase (MMP-9), and vascular endothelial growth factor (VEGF) than the reference group (P<0.05). The monitored group had conspicuously higher Karnofsky Performance Status (KPS) scores than reference group (P<0.05). The thrombocytopenia and gastrointestinal reactions showed no conspicuous difference between two groups (P>0.05). Conclusion: The union therapy of Fuzheng Kang"ai formula and osimertinib can effectively kill tumor cells and alleviate disease symptoms in patients with advanced EGFR mutation positive NSCLC, and has certain clinical value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
